Efficacy of a Newly Modified Short Hydration Method for Gemcitabine and Cisplatin Combination Chemotherapy in Patients with Urothelial Carcinoma

Overview

Journal Oncology

Specialty Oncology

Date 2020 Jun 3

PMID 32485713

Citations 5

Authors

Taku Naiki

Yosuke Sugiyama

Yoshihiko Tasaki

Keitaro Iida

Toshiki Etani

Shuzo Hamamoto

Takashi Nagai

Satoshi Nozaki

Ryosuke Ando

Noriyasu Kawai

Takahiro Yasui

Affiliations

Soon will be listed here.

Abstract

Introduction: Conventional first-line chemotherapy for patients with metastatic urothelial carcinoma (UC) is gemcitabine and cisplatin (GC). However, cisplatin can cause renal failure, necessitating abundant fluid replacement and hospitalization during treatment. Recent evidence exists for short hydration methods in cisplatin-based chemotherapy.

Objective: This study aims to analyze the efficacy of newly established modified short hydration GC (m-shGC) therapy in patients with UC.

Methods: From May 2017 to March 2019, 48 patients with UC who received m-shGC therapy were treated with 1,000 mg/m2 gemcitabine on days 1, 8, and 15, and 70 mg/m2 cisplatin and 2,000 mL fluid replacement on day 1, in each 28-day cycle. We retrospectively evaluated renal function, serum electrolyte abnormalities, and adverse events (AEs) following treatment, and retrospectively compared patients under m-shGC therapy with those under conventional GC (c-GC) therapy from 2015 to 2017. In addition, from April 2019 to August 2019 in a prospective analysis, 15 patients were newly enrolled, and AE profiles and physical activity during m-shGC therapy were quantified using a wearable tracker.

Results: In a retrospective analysis of 101 patients (53 c-GC and 48 m-shGC), patient characteristics were not statistically significant between the two groups. Myelosuppression, including predominant neutropenia and decreased platelets, fatigue, nausea, and constipation were the main common AEs. However, renal function and serum sodium levels in the m-shGC group remained unchanged. Grade 3-4 AEs were not more severe in the m-shGC compared with the c-GC group. Furthermore, in a prospective analysis using a wearable tracker, the amount of walking by patients on day 1 significantly declined. However, immediate recovery occurred reflecting the short hydration.

Conclusion: Our m-shGC therapy has an acceptable AE profile compared with conventional therapy, with UC patients showing good physical activity.

Citing Articles

Hydration Methods for Cisplatin Containing Chemotherapy: A Systematic Review.

Sikking C, Niggebrugge-Mentink K, van der Sman A, Smit R, Bouman-Wammes E, Beex-Oosterhuis M Oncologist. 2023; 29(2):e173-e186.

PMID: 37995306 PMC: 10836314. DOI: 10.1093/oncolo/oyad297.

Planispine A Sensitized Cancer Cells to Cisplatin by Inhibiting the Fanconi Anemia Pathway.

Singh T, Singh N, Devi K, Meiguilungpou R, Khongsai L, Singh L Molecules. 2022; 27(21).

PMID: 36364114 PMC: 9654912. DOI: 10.3390/molecules27217288.

Efficacy of Short Hydration for Intermediate to High-Dose Cisplatin-Based Chemotherapy for Outpatients: SHORTCIS Trial.

Chantharakhit C, Sujaritvanichpong N Asian Pac J Cancer Prev. 2022; 23(10):3323-3330.

PMID: 36308355 PMC: 9924323. DOI: 10.31557/APJCP.2022.23.10.3323.

Modified Glasgow Prognostic Score 2 as a Prognostic Marker in Patients With Metastatic Urothelial Carcinoma.

Nagai T, Naiki T, Isobe T, Sugiyama Y, Etani T, Iida K In Vivo. 2021; 35(5):2793-2800.

PMID: 34410970 PMC: 8408724. DOI: 10.21873/invivo.12565.

Safety of same-day administration of gemcitabine plus cisplatin chemotherapy for urothelial carcinoma.

Tsuru I, Niimi F, Honda S, Azuma T Mol Clin Oncol. 2021; 14(3):57.

PMID: 33604047 PMC: 7849057. DOI: 10.3892/mco.2021.2219.

References

Thompson C, Hoorn E . Hyponatraemia: an overview of frequency, clinical presentation and complications. Best Pract Res Clin Endocrinol Metab. 2012; 26 Suppl 1:S1-6. DOI: 10.1016/S1521-690X(12)00019-X. View

Tiseo M, Martelli O, Mancuso A, Sormani M, Bruzzi P, Di Salvia R . Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma. Tumori. 2007; 93(2):138-44. DOI: 10.1177/030089160709300205. View

Sato J, Morikawa N, Nitanai H, Nagashima H, Nihei S, Yamauti K . Feasibility study of short hydration using oral rehydration solution in cisplatin including chemotherapy of lung cancer. J Pharm Health Care Sci. 2016; 2:6. PMC: 4779197. DOI: 10.1186/s40780-016-0041-z. View

Jan A, Dolan D, Lombardi K, Gupta S . Tolerability of Gemcitabine Plus Cisplatin for Treatment of Urothelial Cancer in the Elderly Population. Clin Genitourin Cancer. 2015; 14(3):e257-63. DOI: 10.1016/j.clgc.2015.09.003. View

Sternberg C, De Mulder P, Schornagel J, Theodore C, Fossa S, Van Oosterom A . Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer. 2005; 42(1):50-4. DOI: 10.1016/j.ejca.2005.08.032. View

Kuroda M, Kotake T, Akaza H, Hinotsu S, Kakizoe T . Efficacy of dose-intensified MEC (methotrexate, epirubicin and cisplatin) chemotherapy for advanced urothelial carcinoma: a prospective randomized trial comparing MEC and M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin). Japanese.... Jpn J Clin Oncol. 1998; 28(8):497-501. DOI: 10.1093/jjco/28.8.497. View

Ouchi A, Asano M, Aono K, Watanabe T, Kato T . Comparison of short and continuous hydration regimen in chemotherapy containing intermediate- to high-dose Cisplatin. J Oncol. 2014; 2014:767652. PMC: 4190919. DOI: 10.1155/2014/767652. View

Kaufman D, Raghavan D, Carducci M, Levine E, Murphy B, Aisner J . Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol. 2000; 18(9):1921-7. DOI: 10.1200/JCO.2000.18.9.1921. View

Sehl M, Sawhney R, Naeim A . Physiologic aspects of aging: impact on cancer management and decision making, part II. Cancer J. 2006; 11(6):461-73. DOI: 10.1097/00130404-200511000-00005. View

10.

von der Maase H, Sengelov L, Roberts J, Ricci S, Dogliotti L, Oliver T . Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005; 23(21):4602-8. DOI: 10.1200/JCO.2005.07.757. View

11.

Strain T, Wijndaele K, Brage S . Physical Activity Surveillance Through Smartphone Apps and Wearable Trackers: Examining the UK Potential for Nationally Representative Sampling. JMIR Mhealth Uhealth. 2019; 7(1):e11898. PMC: 6371078. DOI: 10.2196/11898. View

12.

von der Maase H, Hansen S, Roberts J, Dogliotti L, Oliver T, Moore M . Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000; 18(17):3068-77. DOI: 10.1200/JCO.2000.18.17.3068. View

13.

Lavole A, Danel S, Baudrin L, Gounant V, Ruppert A, Epaud C . Routine administration of a single dose of cisplatin ≥ 75 mg/m2 after short hydration in an outpatient lung-cancer clinic. Bull Cancer. 2012; 99(4):E43-8. DOI: 10.1684/bdc.2012.1555. View

14.

Nogic J, Thein P, Cameron J, Mirzaee S, Ihdayhid A, Nasis A . The utility of personal activity trackers (Fitbit Charge 2) on exercise capacity in patients post acute coronary syndrome [UP-STEP ACS Trial]: a randomised controlled trial protocol. BMC Cardiovasc Disord. 2017; 17(1):303. PMC: 5747185. DOI: 10.1186/s12872-017-0726-8. View

15.

Sakaida E, Iwasawa S, Kurimoto R, Ebata T, Imai C, Oku T . Safety of a short hydration method for cisplatin administration in comparison with a conventional method-a retrospective study. Jpn J Clin Oncol. 2016; 46(4):370-7. PMC: 4886127. DOI: 10.1093/jjco/hyv203. View

16.

Leth S, Hansen J, Nielsen O, Dinesen B . Evaluation of Commercial Self-Monitoring Devices for Clinical Purposes: Results from the Future Patient Trial, Phase I. Sensors (Basel). 2017; 17(1). PMC: 5298782. DOI: 10.3390/s17010211. View

17.

Hartman S, Natarajan L, Palmer B, Parker B, Patterson R, Sears D . Impact of increasing physical activity on cognitive functioning in breast cancer survivors: Rationale and study design of Memory & Motion. Contemp Clin Trials. 2015; 45(Pt B):371-376. PMC: 4674350. DOI: 10.1016/j.cct.2015.09.021. View

18.

Azuma T, Matayoshi Y, Sato Y, Sato Y, Nagase Y, Oshi M . The safety and effect of chemotherapy with short hydration for urothelial cancer on patients' quality of life. Jpn J Clin Oncol. 2016; 46(10):958-963. DOI: 10.1093/jjco/hyw097. View

19.

Charlson M, Pompei P, Ales K, MacKenzie C . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-83. DOI: 10.1016/0021-9681(87)90171-8. View

20.

Sawhney R, Sehl M, Naeim A . Physiologic aspects of aging: impact on cancer management and decision making, part I. Cancer J. 2006; 11(6):449-60. DOI: 10.1097/00130404-200511000-00004. View